Phase 2
-
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
Phase 2 · randomised · 122 people · 1 site in China · Recruiting now
-
Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Tislelizumab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement
Phase 2 · 51 people · 2 sites in China · Recruiting now
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
Phase 2 · 64 people · 4 sites in United States · Recruiting now
-
SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）
Phase 2 · 31 people · 1 site in China · Recruiting now
-
A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer
Phase 2 · 44 people · 1 site in China · Recruiting now
-
Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Phase 2 · 48 people · 1 site in China · Recruiting now
-
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 2 · 220 people · 24 sites in 7 countries · Recruiting now